ClinicalTrials.gg
CompletedNCT00104052Updated Apr 4, 2017Results posted

Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)

A Phase 3 interventional study of peginterferon alfa-2b (PEG2b) (SCH 54031) and ribavirin (SCH 18908) in Hepatitis C, Chronic, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-04-04.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
107
Allocation
Non-randomized
Ages
3 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Hepatitis C, Chronic.

Enrollment
17th of 39
107 · median 99
Started
2005
with 7 others
Phase 3
22 of 40
none open now
Registered
3rd of 40
by date
Lead sponsor
25 of 40
Merck Sharp & Dohme LLC

Among the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic, this one is the 17th largest by enrollment of the 39 interventional ones that give a count, is one of 8 that started in 2005, is one of 22 in phase 3, and was the 3rd registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2b

peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 3 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic as a file.
02

Study summary

The primary objective is to assess the safety, efficacy and tolerability of the combination of PEG-Intron plus REBETOL in pediatric subjects with chronic hepatitis C. The secondary objective is to measure the multiple-dose pharmacokinetics of PEG-Intron and REBETOL in pediatric subjects with chronic hepatitis C.

Read the detailed description

This global, multicenter, open-label Phase 3 study will evaluate the safety, efficacy and tolerability of PEG-Intron plus REBETOL in previously untreated pediatric subjects, ages 3 through 17 years, with chronic hepatitis C.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children age 3-17 years old
  • Individuals weighing ≤ 90 kg
  • Previously untreated children with chronic (HCV RNA qPCR plasma positive)
  • Individuals with any HCV (hepatitis C virus) genotype
  • Hematology laboratory results of:

    • (HGB) ≥ 11 g/dL for females or ≥ 12g/dL for males,
    • White Blood Cell Count (WBC) ≥ 3,000/mm\^3,
    • Neutrophils ≥ 1,500/mm\^3,
    • ≥ 100,000/mm\^3
  • Chemistry laboratory results of:

    • Normal Thyroid Stimulating Hormone (TSH), albumin, creatinine, and ,
    • Antinuclear antibody (ANA) ≤ 1:160,
    • Fasting Glucose 70-140 mg/dL. Note: If glucose levels are between 116-140 mg/dL or an individual has diabetes, must be ≤ 8.5%
  • Compensated liver disease
  • Historic or pre-treatment liver slides available
  • No significant co-existing psychiatric disease
  • Those with diabetes, hypertension, or birth prior to 32 weeks gestational age must have normal eye exams and retinal photographs (these will be done as part of the study before hepatitis C treatment is given)
  • Patients and partners of patients willing to use adequate during the course of the study
  • Abstain from alcohol and any other illicit drugs

Exclusion criteria

Exclusion Criteria:

  • Serum >10 times the within the 6 months prior to study
  • Previous treatment
  • Children with liver disease not caused by hepatitis C
  • Most recent liver is normal
  • Individuals infected with the virus and/or (HIV)
  • Known blood disorders such as hemoglobinopathy, coagulopathy, or G6PD deficiency
  • Known immunodeficiency disorders requiring immunoglobulin therapy
  • Body organ transplant
  • Any known or suspected cancer within the past 5 years
  • Children with chronic pulmonary disease
  • Individuals who have a medical condition that would likely require systemic
  • Those with a history of central nervous system (CNS) trauma or seizure disorders
  • Individuals with pre-existing psychiatric disorders including but not limited to moderate to severe depression
  • Current or previous use of lithium or antipsychotic drugs
  • Patients with (ECG) abnormalities and/or significant cardiovascular dysfunction (e.g., angina, congestive heart failure, recent myocardial infarction, uncontrolled hypertension, significant arrhythmia, cardiac sequelae from Kawasaki disease, cardiomyopathy, and/or history of congenital heart disease)
  • Insulin-dependent diabetes mellitus or poorly controlled non-insulin dependent diabetes mellitus
  • Immunologically mediated disease (e.g., inflammatory bowel disease [Crohn's disease, ulcerative colitis], rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, hemolytic anemia, scleroderma, severe psoriasis, or symptomatic thyroid disorder)
  • History of substance abuse, including alcohol (e.g., binge drinking, blackouts), intravenous drugs and inhaled drugs
  • Subjects who have a history of pregnancy or who are pregnant and/or breast feeding. Subjects who intend to become pregnant during the study period. Subjects with partners who intend to become pregnant during the study period
  • Subjects with clinically significant retinal abnormalities such as known retinopathy of prematurity or other retinopathies
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    PEG-Intron alfa 2b (PEG2b) plus REBETOL (RBV)

    PEG2b 1.5 μg/kg/wk given subcutaneously (once weekly) and RBV 400-1200 mg/day by mouth divided in 2 daily doses (administered twice daily with food, dosed 12 hours apart) for 48 weeks. Subjects treated up to 48 weeks and followed for additional 24 weeks after the end of treatment (total of 72 weeks study participation).

    Biological: peginterferon alfa-2b (PEG2b) (SCH 54031) · Drug: ribavirin (SCH 18908)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With a Sustained Virologic Response (SVR) at 24 Weeks Post-treatment

    SVR is defined as undetectable hepatitis C virus ribonucleic acid (HCV-RNA) at 24 weeks post-treatment

    Time frame: Up to 48-week treatment duration. Follow-up of 24 weeks.

07

Results

Posted Mar 9, 2009

Participant flow

Participant flow — Overall Study
MilestonePEG-Intron Plus REBETOL
Started107
Completed78
Not completed29
Withdrew: Adverse event1
Withdrew: Lack of efficacy26
Withdrew: Discontinuation unrelated to treatment2

Outcome measures

PrimaryNumber of Participants With a Sustained Virologic Response (SVR) at 24 Weeks Post-treatment

SVR is defined as undetectable hepatitis C virus ribonucleic acid (HCV-RNA) at 24 weeks post-treatment

Time frame:
Up to 48-week treatment duration. Follow-up of 24 weeks.
Reported as:
Number · Participants
Number of Participants With a Sustained Virologic Response (SVR) at 24 Weeks Post-treatment
ParticipantsPEG-Intron Plus REBETOL
Number of Participants With a Sustained Virologic Response (SVR) at 24 Weeks Post-treatment70
Statistical analysis
  • PEG-Intron Plus REBETOL · Normal approximation to the binomial: 0.654 · 95% CI 0.564 to 0.744

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PEG-Intron Plus REBETOL—3/107 (2.8%)107/107 (100%)
Most frequent serious events
Most frequent serious events
EventPEG-Intron Plus REBETOL
PALPITATIONSCardiac disorders1/107
CARBON MONOXIDE POISONINGInjury, poisoning and procedural complications1/107
FALLInjury, poisoning and procedural complications1/107
SYNCOPENervous system disorders1/107
Most frequent other events
Showing 10 of 43
Most frequent other events
EventPEG-Intron Plus REBETOL
PYREXIAGeneral disorders86/107
HEADACHENervous system disorders71/107
VOMITINGGastrointestinal disorders36/107
NEUTROPENIABlood and lymphatic system disorders35/107
FATIGUEGeneral disorders32/107
INJECTION SITE ERYTHEMAGeneral disorders31/107
ANOREXIAMetabolism and nutrition disorders31/107
ABDOMINAL PAINGastrointestinal disorders28/107
DECREASED APPETITEMetabolism and nutrition disorders24/107
COUGHRespiratory, thoracic and mediastinal disorders24/107

Baseline characteristics

Age, Continuous
Age, Continuous(years)PEG-Intron Plus REBETOL
Mean9.7 ± 4.0
Sex: Female, Male
Sex: Female, Male(Participants)PEG-Intron Plus REBETOL
Female56
Male51
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Haber B, Alonso E, Pedreira A, Rodriguez-Baez N, Ciocca M, Lacaille F, Lang T, Gonzalez T, Goodman Z, Yang Z, Jackson B, Noviello S, Albrecht JK. Long-Term Follow-Up of Children Treated With Peginterferon and Ribavirin for Hepatitis C Virus Infection. J Pediatr Gastroenterol Nutr. 2017 Jan;64(1):89-94. doi: 10.1097/MPG.0000000000001239. PubMed 27111344 ↗
  • Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, Shelton M, Kerkar N, Galoppo M, Pedreira A, Rodriguez-Baez N, Ciocca M, Lachaux A, Lacaille F, Lang T, Kullmer U, Huber WD, Gonzalez T, Pollack H, Alonso E, Broue P, Ramakrishna J, Neigut D, Valle-Segarra AD, Hunter B, Goodman Z, Xu CR, Zheng H, Noviello S, Sniukiene V, Brass C, Albrecht JK. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol. 2010 Apr;52(4):501-7. doi: 10.1016/j.jhep.2010.01.016. Epub 2010 Feb 4. PubMed 20189674 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2005, a primary completion of Nov 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2009, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2005
First posted
Feb 23, 2005
Start
Feb 2005
Primary completionActual
Nov 2007
CompletionActual
Nov 2007
Results first posted
Mar 9, 2009
Last update
Apr 4, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00104052
Responsible party
Sponsor
First posted
Feb 23, 2005
Start date
Feb 2005
Primary completion
Nov 2007
Completion
Nov 2007
Results posted
Mar 9, 2009
Last update
Apr 4, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2b · Ribavirin

Start the discussion